Sign in →

Test Code TTFB Testosterone, Total, Bioavailable, and Free, Serum

Additional Codes

CNE Order Code: Testosterone, Total, Bio+ Free

Test Down Notes

This test is temporarily unavailable. For additional details, see test announcement here.

Reporting Name

Testosterone, Total, Bio, Free, S

Useful For

Second- or third-order test for evaluating testosterone status (eg, when abnormalities of sex hormone-binding globulin are present)

Profile Information

Test ID Reporting Name Available Separately Always Performed
TTST Testosterone, Total, S Yes Yes
FRTST Testosterone, Free, S No Yes
BATS Testosterone, Bioavailable, S No Yes

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Specimen Type

Serum Red


Ordering Guidance


The preferred test for diagnosis of mild abnormalities of testosterone homeostasis, particularly if abnormalities in sex hormone-binding globulin function or levels are present, is TTBS / Testosterone, Total and Bioavailable, Serum.



Necessary Information


Patient's age and sex are required.



Specimen Required


Supplies: Sarstedt Aliquot Tube, 5 mL (T914)

Collection Container/Tube: Red top (serum gel/SST are not acceptable)

Submission Container/Tube: Plastic vial

Specimen Volume: 3.5 mL

Collection Instructions: Centrifuge and aliquot serum into a plastic vial


Specimen Minimum Volume

2 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Red Refrigerated (preferred) 14 days
  Frozen  60 days

Reference Values

TESTOSTERONE, TOTAL

Males

0-5 months: 75-400 ng/dL

6 months-9 years: <7-20 ng/dL

10-11 years: <7-130 ng/dL

12-13 years: <7-800 ng/dL

14 years: <7-1,200 ng/dL

15-16 years: 100-1,200 ng/dL

17-18 years: 300-1,200 ng/dL

≥19 years: 240-950 ng/dL

Tanner Stages*

I (prepubertal): <7-20

II: 8-66

III: 26-800

IV: 85-1,200

V (young adult): 300-950

 

Females

0-5 months: 20-80 ng/dL

6 months-9 years: <7-20 ng/dL

10-11 years: <7-44 ng/dL

12-16 years: <7-75 ng/dL

17-18 years: 20-75 ng/dL

≥19 years: 8-60 ng/dL

Tanner Stages*

I (prepubertal): <7-20

II: <7-47

III: 17-75

IV: 20-75

V (young adult): 12-60

*Puberty onset (transition from Tanner stage I to Tanner stage II) occurs for boys at a median age of 11.5 (±2) years and for girls at a median age of 10.5 (±2) years. There is evidence that it may occur up to 1 year earlier in obese girls and in African American girls. For boys, there is no definite proven relationship between puberty onset and body weight or ethnic origin. Progression through Tanner stages is variable. Tanner stage V (young adult) should be reached by age 18.

 

TESTOSTERONE, FREE

Males (adult):

20-<25 years: 5.25-20.7 ng/dL

25-<30 years: 5.05-19.8 ng/dL

30-<35 years: 4.85-19.0 ng/dL

35-<40 years: 4.65-18.1 ng/dL

40-<45 years: 4.46-17.1 ng/dL

45-<50 years: 4.26-16.4 ng/dL

50-<55 years: 4.06-15.6 ng/dL

55-<60 years: 3.87-14.7 ng/dL

60-<65 years: 3.67-13.9 ng/dL

65-<70 years: 3.47-13.0 ng/dL

70-<75 years: 3.28-12.2 ng/dL

75-<80 years: 3.08-11.3 ng/dL

80-<85 years: 2.88-10.5 ng/dL

85-<90 years: 2.69-9.61 ng/dL

90-<95 years: 2.49-8.76 ng/dL

95-100+ years: 2.29-7.91 ng/dL

 

Males (children):

<1 year: Term infants

1-15 days: 0.20-3.10 ng/dL*

16 days-1 year: Values decrease gradually from newborn (0.20-3.10 ng/dL) to prepubertal levels

*Forest MG, Cathiard AM, Bertrand JA. Total and unbound testosterone levels in the newborn and in normal and hypogonadal children: use of a sensitive radioimmunoassay for testosterone. J Clin Endocrinol Metab. 1973;36(6):1132-1142 

1-8 years: <0.13 ng/dL

9 years: <0.13-0.45 ng/dL

10 years: <0.13-1.26 ng/dL

11 years: <0.13-5.52 ng/dL

12 years: <0.13-9.28 ng/dL

13 years: <0.13-12.6 ng/dL

14 years: 0.48-15.3 ng/dL

15 years: 1.62-17.7 ng/dL

16 years: 2.93-19.5 ng/dL

17 years: 4.28-20.9 ng/dL

18 years: 5.40-21.8 ng/dL

19 years: 5.36-21.2 ng/dL

 

Females (adult):

20-<25 years: <0.13-1.08 ng/dL

25-<30 years: <0.13-1.06 ng/dL

30-<35 years: <0.13-1.03 ng/dL

35-<40 years: <0.13-1.00 ng/dL

40-<45 years: <0.13-0.98 ng/dL

45-<50 years: <0.13-0.95 ng/dL

50-<55 years: <0.13-0.92 ng/dL

55-<60 years: <0.13-0.90 ng/dL

60-<65 years: <0.13-0.87 ng/dL

65-<70 years: <0.13-0.84 ng/dL

70-<75 years: <0.13-0.82 ng/dL

75-<80 years: <0.13-0.79 ng/dL

80-<85 years: <0.13-0.76 ng/dL

85-<90 years: <0.13-0.73 ng/dL

90-<95 years: <0.13-0.71 ng/dL

95-100+ years: <0.13-0.68 ng/dL

 

Females (children):

<1 year: Term infants

1-15 days: <0.13-0.25 ng/dL*

16 days-1 year: Values decrease gradually from newborn (<0.13-0.25 ng/dL) to prepubertal levels

*Forest MG, Cathiard AM, Bertrand JA. Total and unbound testosterone levels in the newborn and in normal and hypogonadal children: use of a sensitive radioimmunoassay for testosterone. J Clin Endocrinol Metab. 1973;36(6):1132-1142

 

1-4 years: <0.13 ng/dL

5 years: <0.13 ng/dL

6 years: <0.14 ng/dL

7 years: <0.13-0.23 ng/dL

8 years: <0.13-0.34 ng/dL

9 years: <0.13-0.46 ng/dL

10 years: <0.13-0.59 ng/dL

11 years: <0.13-0.72 ng/dL

12 years: <0.13-0.84 ng/dL

13 years: <0.13-0.96 ng/dL

14 years: <0.13-1.06 ng/dL

15-18 years: <0.13-1.09 ng/dL

19 years: <0.13-1.08 ng/dL

 

TESTOSTERONE, BIOAVAILABLE

Males

≤19 years: Not established

20-29 years: 83-257 ng/dL

30-39 years: 72-235 ng/dL

40-49 years: 61-213 ng/dL

50-59 years: 50-190 ng/dL

60-69 years: 40-168 ng/dL

≥70 years: Not established

 

Females (non-oophorectomized)

≤19 years: Not established

20-50 years (on oral estrogen): 0.80-4.0 ng/dL

20-50 years (not on oral estrogen): 0.80-10 ng/dL

>50 Years: Not established

Day(s) Performed

Monday through Saturday

CPT Code Information

84402

84403

84410

LOINC Code Information

Test ID Test Order Name Order LOINC Value
TTFB Testosterone, Total, Bio, Free, S 58716-2

 

Result ID Test Result Name Result LOINC Value
82978 Testosterone, Bioavailable, S 2990-0
3631 Testosterone Free 2991-8
8533 Testosterone, Total, S 2986-8

Interpretation

Total testosterone and general interpretation of testosterone abnormalities:

 

In male patients:

Decreased testosterone levels indicate partial or complete hypogonadism. Serum testosterone levels are usually below the reference range. The cause is either primary or secondary/tertiary (pituitary/hypothalamic) testicular failure.

 

Primary testicular failure is associated with increased luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels, and decreased total, bioavailable, and free testosterone levels. Causes include:

-Genetic causes (eg, Klinefelter syndrome, XXY males)

-Developmental causes (eg, testicular maldescent)

-Testicular trauma or ischemia (eg, testicular torsion, surgical mishap during hernia operations)

-Infections (eg, mumps)

-Autoimmune diseases (eg, autoimmune polyglandular endocrine failure)

-Metabolic disorders (eg, hemochromatosis, liver failure)

-Orchidectomy

 

Secondary/tertiary hypogonadism, also known as hypogonadotropic hypogonadism, shows low testosterone and low, or inappropriately "normal," LH/FSH levels; causes include:

-Inherited or developmental disorders of hypothalamus and pituitary (eg, Kallmann syndrome, congenital hypopituitarism)

-Pituitary or hypothalamic tumors

-Hyperprolactinemia of any cause

-Malnutrition or excessive exercise

-Cranial irradiation

-Head trauma

-Medical or recreational drugs (eg, estrogens, gonadotropin releasing hormone [GnRH] analogs, cannabis)

 

Increased testosterone levels:

-In prepubertal boys, increased levels of testosterone are seen in precocious puberty. Further workup is necessary to determine the cause of precocious puberty

-In men, testicular or adrenal tumors or androgen abuse might be suspected if testosterone levels exceed the upper limit of the normal range by more than 50%.

 

Monitoring of testosterone replacement therapy:

Aim of treatment is normalization of serum testosterone and LH. During treatment with depot-testosterone preparations, trough levels of serum testosterone should still be within the normal range, while peak levels should not be significantly above the normal young adult range.

 

Monitoring of antiandrogen therapy:

Aim is usually to suppress testosterone levels to castrate levels or below (no more than 25% of the lower reference range value).

 

In female patients:

Decreased testosterone levels may be observed in primary or secondary ovarian failure, analogous to the situation in men, alongside the more prominent changes in female hormone levels. Most women with oophorectomy have a significant decrease in testosterone levels.

 

Increased testosterone levels may be seen in:

-Congenital adrenal hyperplasia: non-classical (mild) variants may not present in childhood but during or after puberty. In addition to testosterone, multiple other androgens or androgen precursors are elevated, such as 17-hydroxyprogesterone (OHPG / 17-Hydroxyprogesterone, Serum), often to a greater degree than testosterone.

-Prepubertal girls: analogous to boys, but at lower levels, increased levels of testosterone are seen in precocious puberty.

-Ovarian or adrenal neoplasms: high estrogen values also may be observed, and LH and FSH are low or "normal." Testosterone-producing ovarian or adrenal neoplasms often produce total testosterone values greater than 200 ng/dL.

-Polycystic ovarian syndrome: hirsutism, acne, menstrual disturbances, insulin resistance and frequently, obesity form part of this syndrome. Total testosterone levels may be normal or mildly elevated and, uncommonly, greater than 200 ng/dL.

 

Monitoring of testosterone replacement therapy:

The efficacy of testosterone replacement in females is under study. If it is used, total testosterone levels should always be kept within the normal range for females. Bioavailable or free testosterone levels also should be monitored to avoid overtreatment.

 

Monitoring of antiandrogen therapy:

Antiandrogen therapy is most frequently employed in the management of mild-to-moderate idiopathic female hyperandrogenism, as seen in polycystic ovarian syndrome. Total testosterone levels are a relatively crude guideline for therapy and can be misleading. Therefore, bioavailable or free testosterone also should be monitored to ensure treatment adequacy. However, there are no universally agreed biochemical endpoints and the primary treatment end point is the clinical response.

 

Bioavailable and Free Testosterone:

Usually, bioavailable and free testosterone levels parallel the total testosterone levels. However, a number of conditions and medications are known to increase or decrease the sex hormone-binding globulin (SHBG) concentration, which may cause total testosterone concentration to change without necessarily influencing the bioavailable or free testosterone concentration or vice versa:

-Treatment with corticosteroids and sex steroids (particularly oral conjugated estrogen) can result in changes in SHBG levels and availability of sex-steroid binding sites on SHBG. This may make diagnosis of subtle testosterone abnormalities difficult.

-Inherited abnormalities in SHBG binding

-Liver disease and severe systemic illness

-In pubertal boys and adult men, mild decreases of total testosterone without LH abnormalities can be associated with delayed puberty or mild hypogonadism. In this case, either bioavailable or free testosterone measurements are better indicators of mild hypogonadism than determination of total testosterone levels.

-In polycystic ovarian syndrome and related conditions, there is often significant insulin resistance, which is associated with low SHBG levels. Consequently, bioavailable or free testosterone levels may be more significantly elevated.

 

Either bioavailable or free testosterone should be used as supplemental tests to total testosterone in the above situations. The correlation coefficient between bioavailable and free testosterone (by equilibrium dialysis) is 0.9606. However, bioavailable testosterone is usually the preferred test, as it more closely reflects total bioactive testosterone, particularly in older men. Men at this age have elevated SHBG levels and may also have varying albumin levels due to coexisting illnesses.

Report Available

3 to 7 days

Reject Due To

Gross hemolysis OK
Gross lipemia Reject
Gross icterus OK

Method Name

FRTST: Equilibrium Dialysis/Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)

TTST: Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)

BATS: Differential Precipitation/Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)